By Abigail Townsend
Date: Wednesday 20 Oct 2021
(Sharecast News) - Biogen raised its full-year earnings guidance on Wednesday, despite weak sales of breakthrough Alzheimer's drug Aduhelm.
Currency | US Dollars |
Share Price | $ 137.40 |
Change Today | $ 2.46 |
% Change | 1.82 % |
52 Week High | $206.18 |
52 Week Low | $118.84 |
Volume | 617,073 |
Shares Issued | 145.80m |
Market Cap | $20,033m |
RiskGrade | 259 |
Strong Buy | 7 |
Buy | 6 |
Neutral | 21 |
Sell | 1 |
Strong Sell | 0 |
Total | 35 |
Time | Volume / Share Price |
13:17 | 100 @ $137.40 |
13:17 | 100 @ $137.47 |
13:17 | 100 @ $137.47 |
13:16 | 100 @ $137.53 |
13:16 | 150 @ $137.46 |
You are here: research